Clinical DevelopmentThe speed of clinical development and encouraging preclinical data are viewed positively for NextCure's LNCB74.
EfficacyPreclinical results have demonstrated superior efficacy vs the val-cit linker MMAE ADC in ovarian cancer and breast cancer models, showing potential for LNCB74 to be more efficacious.
Safety ProfileNextCure is enrolling patients in Cohort 2 in Phase 1, which is taken as a positive signal of safety with no DLTs likely observed.